Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

(CELG)

   0 (0%) 12-31 19:00
Open: Pre. Close:
High: Low:
Volume: Market Cap: 0(M)

Technical analysis

as of: 2022-12-05 1:18:16 PM
Overall:       
Stoxline posted a STRONG SELL today, same as yesterday. Downward movement continues.
Target: Six months: 109.06     One year: 114.33
Support: Support1: 86.08    Support2: 71.61
Resistance: Resistance1: 93.37    Resistance2: 97.88
Pivot: 93.89
Moving Average: MA(5): 93.54     MA(20): 93.21
MA(100): 82.58     MA(250): 0
MACD: MACD(12,26): 0.9     Signal(9): 1.5
Stochastic oscillator: %K(14,3): 39.9     %D(3): 58.2
RSI: RSI(14): 45.9
52-week: High: 97.88  Low: 40.95
Average Vol(K): 3-Month: 2,167 (K)  10-Days: 1,450 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CEG ] has closed above bottom band by 11.2%. Bollinger Bands are 33.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 93.67 - 94.2 94.2 - 94.78
Low: 89.55 - 90.14 90.14 - 90.78
Close: 90.93 - 91.95 91.95 - 93.07

Company Description

Headline News

Mon, 05 Dec 2022
Beta-thalassemia (B-thal) Market will generate new growth opportunities 2022-2028 | Celgene Corp., BlueBird Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Ionis Pharmaceuticals - Digital Journal

Mon, 05 Dec 2022
Patent settlement and licence agreements - Lexology

Fri, 02 Dec 2022
Vaxxinity will push for approval of COVID booster after trial shows noninferiority to market leader Pfizer - FierceBiotech

Fri, 02 Dec 2022
Cellectar Biosciences announces former Celgene-BMS exec as new chief commercial officer - ROI-NJ.com

Fri, 02 Dec 2022
Philip Tagari switches Amgen's discovery lab for insitro's machine learning tools; CEO Joaquin Duato to chair J&J's board - Endpoints News

Wed, 30 Nov 2022
Endometrial Cancer Therapeutics Market 2021 Growth Drivers and Future Outlook | Top Brands Bristol-Myers Squibb Company, Merck KGaA, ArQule Inc., CELGENE, Janssen Pharmaceuticals, Pfizer, etc – Skegness Siren - Skegness Siren

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange: 
Sector: 
Industry: 
Shares Out. 327 (M)
Shares Float 327 (M)
% Held by Insiders 0.2 (%)
% Held by Institutions 83.3 (%)
Shares Short 4,720 (K)
Shares Short P.Month 4,120 (K)

Stock Financials

EPS 2.15
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 33.02
Profit Margin (%) -0.7
Operating Margin (%) 0.1
Return on Assets (ttm) 0
Return on Equity (ttm) -1.4
Qtrly Rev. Growth 37.2
Gross Profit (p.s.) 8.4
Sales Per Share 69.23
EBITDA (p.s.) 5.56
Qtrly Earnings Growth 0
Operating Cash Flow -2,240 (M)
Levered Free Cash Flow 151 (M)

Stock Valuations

PE Ratio 42.17
PEG Ratio 1.2
Price to Book value 2.74
Price to Sales 1.3
Price to Cash Flow -13.24

Stock Dividends

Dividend 0.14
Forward Dividend 0
Dividend Yield 0.1%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.